Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by ...

Eli Lilly hit a $1 trillion valuation, driven by demand for Zepbound and Mounjaro. The first health-care firm ever to join ...

The pharmaceutical giant Eli Lilly's stock has been riding the skyrocketing demand for its weight loss injection Zepbound and ...

The direct-to-employer (DTE) is an industry first for FDA-approved weight-loss drugs like Novo Nordisk's Wegovy (semaglutide) ...

Discover six obesity deals made so far in 2025, with dealmaking activity in the field being largely dominated by big pharma ...

Health, a leader in virtual cardiometabolic care, today announced a new offering designed to make access to obesity management medications and care more sustainable for employers. The "No-Barriers ...

Eli Lilly & Co. and Novo Nordisk A/S plan to start selling their popular obesity shots to employers through a new approach ...

Weight-loss drugs like Wegovy and Zepbound often cause nausea and other side effects. Brain scientists are looking for ways ...

In summary, under the Trump plan, the U.S. health system continues to fail Americans — by not viewing obesity as a disease, ...

Novo Nordisk (NVO) is deeply undervalued after a 43% YTD decline, despite strong fundamentals and global obesity market ...

You’re reading The Checkup With Dr. Wen, a newsletter on how to navigate medical and public health challenges. Click here to ...

Remedy Meds is an online consumer health and pharmacy platform that provides access to compounded glucagon-like peptide-one ...